Transforming Hypertension Management with AVIM Therapy
At the forefront of biomedical innovation, Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is set to showcase its groundbreaking Atrioventricular Interval Modulation (AVIM) Therapy at a significant event focused on addressing hypertensive heart disease. This therapy offers hope for patients suffering from uncontrolled hypertension, which is recognized as a leading risk factor for heart complications across the globe.
Key Presentation Highlights
During the Georgia Innovation Summit, Dr. Avi Fischer, Senior Vice President of Medical Affairs and Innovation at Orchestra BioMed, will deliver the keynote presentation on the clinical evidence supporting AVIM Therapy. The session is aimed at healthcare professionals and stakeholders, offering insights into how this innovative therapy could drastically alter the landscape of hypertension treatment.
Clinical Evidence Showcasing AVIM Therapy
The presentation will detail promising data from both pilot studies and long-term follow-ups. This evidence highlights major improvements in blood pressure control and cardiac function for individuals treated with AVIM Therapy:
- Clinically Significant Blood Pressure Reduction: Results from MODERATO I and II pilot studies demonstrated substantial decreases in ambulatory systolic blood pressure (aSBP) and office measurements, providing robust evidence of the therapy's effectiveness over time.
- Positive Cardiac Function Outcomes: Patients experienced improved cardiac hemodynamics, with notable reductions in heart rate and cardiac volumes, which supports the therapy's safety and reliability.
- Improving Diastolic Function: Echocardiographic assessments indicate enhanced heart relaxation and compliance, marking progress in treating hypertensive heart disease.
- Durable Results: Follow-ups showed that the benefits of AVIM Therapy could persist even after deactivation, implying a long-lasting impact on patient health.
Partnerships Enhancing Therapy Accessibility
Orchestra BioMed’s collaboration with Medtronic (NYSE: MDT) is instrumental in advancing the development and commercialization of AVIM Therapy. This partnership aims to make AVIM Therapy accessible to an estimated global patient population exceeding 750,000 individuals annually who are in need of pacemaker interventions due to uncontrolled hypertension.
About Orchestra BioMed
With a mission to accelerate high-impact technologies, Orchestra BioMed complements its internal development efforts with strategic partnerships with leading medical device companies. Their innovative focus is on bringing therapies like AVIM Therapy to the market while also managing projects related to the Virtue Sirolimus AngioInfusion Balloon (SAB). This balloon therapy addresses atherosclerotic artery disease, further solidifying Orchestra BioMed's commitment to revolutionizing cardiovascular care.
Frequently Asked Questions
What is AVIM Therapy?
AVIM Therapy is an investigational treatment designed to lower blood pressure and improve cardiac function through modulation techniques compatible with dual-chamber pacemakers.
How does AVIM Therapy impact patients with hypertension?
This therapy has demonstrated the ability to significantly reduce blood pressure while enhancing overall cardiac health, which can ultimately improve long-term outcomes for patients.
What is the significance of the keynote presentation?
The keynote presentation will underline the critical advancements made in hypertensive disease management through AVIM Therapy, solidifying its role as a breakthrough treatment.
Who is presenting the data at the summit?
Dr. Avi Fischer, an expert in medical innovation and affairs at Orchestra BioMed, will present the findings and implications of AVIM Therapy during the summit.
How can I learn more about Orchestra BioMed?
For additional information or inquiries about their innovative therapies, reach out to Orchestra BioMed via their website or contact details.
